In initial human trials, synthetic vaccines have induced humoral immunity sufficient to prevent clinical infection in some cases and delay it in others. Progress in induction of cellular immunity is also noteworthy with identification of determinants recognized by T cells. Antigenic variation and consequent blunting of immunogenicity may not be as troublesome as feared.